Trials, real-world evidence & partnering.
From biomarker hypothesis to real-world answer.
OnKommon pairs a molecular intelligence platform with an exclusive clinical partner (KPCIRC) and a growing, consented patient network. For life-sciences partners, that combination shortens the distance between a biomarker hypothesis and a real-world answer — in trial recruitment, evidence generation, and diagnostic strategy.
1 · Partnering with OnKommon
OnKommon pairs a molecular intelligence platform with an exclusive clinical partner (KPCIRC) and a growing, consented patient network. For life-sciences partners, that combination shortens the distance between a biomarker hypothesis and a real-world answer — in trial recruitment, evidence generation, and diagnostic strategy.
2 · Biomarker-matched trial recruitment
Our TrialGraph™ layer matches comprehensively-profiled patients to eligibility criteria at the molecular level, and our clinical partner can support site-level conduct. That means faster identification of the right patients for the right study — including rare-biomarker cohorts that are hard to reach through conventional channels.
Molecular pre-screening
Molecular pre-screening against protocol eligibility.
Consented patient population
Access to a consented, comprehensively-profiled patient population.
Clinical-partner support
Clinical-partner support for enrolment and conduct.
3 · Real-world evidence
Because OnKommon follows patients longitudinally — baseline profiling, serial Sentinel monitoring, outcomes — it generates linked clinicogenomic real-world datasets. With appropriate consent and governance, these support outcomes research, drug-performance studies, and post-market surveillance in the Indian population, where such data is scarce.
4 · Companion diagnostics & biomarker strategy
We support biomarker discovery and companion-diagnostic strategy — from exploratory analyses on consented cohorts to structured biomarker validation — backed by our interpretation engine and clinical governance.
5 · Interpretation-as-a-service
Through the Decipher pathway, OnKommon can provide interpretation and molecular-tumour-board sign-out on data generated elsewhere — a way for laboratories, hospitals, and programmes to add decision-grade reporting without building an interpretation stack of their own.
6 · Bespoke genetic screening services
For corporate, insurer, and population-health partners, OnKommon can design and run targeted genetic screening programmes — for example hereditary-cancer risk screening — with counselling and clear governance built in. We help define what to screen for, why, and how results are responsibly returned.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →